

CORRECTION

Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel

Qian Li, Mei Liu, Fei Ma, Yang Luo, Ruigang Cai, Liming Wang, Ningzhi Xu, Binghe Xu

There is an error in reference 29. The correct reference is: Mo W, Zhang J, Li X, Meng D, Gao Y, Yang S, et al. (2013) Identification of Novel AR-Targeted MicroRNAs Mediating Androgen Signalling through Critical Pathways to Regulate Cell Viability in Prostate Cancer. PLoS ONE 8(2): e56592.

Reference

1. Li Q, Liu M, Ma F, Luo Y, Cai R, Wang L, et al. (2014) Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel. PLoS ONE 9(8): e104870. doi:[10.1371/journal.pone.0104870](https://doi.org/10.1371/journal.pone.0104870) PMID: [25137071](https://pubmed.ncbi.nlm.nih.gov/25137071/)



OPEN ACCESS

Citation: Li Q, Liu M, Ma F, Luo Y, Cai R, Wang L, et al. (2015) Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel. PLoS ONE 10(8): e0136826. doi:[10.1371/journal.pone.0136826](https://doi.org/10.1371/journal.pone.0136826)

Published: August 25, 2015

Copyright: © 2015 Li et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.